Gotham Therapeutics has secured $54m in series A financing to develop its RNA-modifying protein therapies. Epitranscriptomics are similar in some ways to epigenetics in terms of chemical processes and enzymes involved, differing from epigenetics in their focus on transcribing RNA into proteins rather than transcribing DNA into RNA. The investment was led by Versant Ventures, Forbion and S.R. One, with support from Celgene and Alexandria Venture Investments. “Versac’s investments are a testament to the strength of our team at Gotham Therapeutics,” said Dr. David A. Cohen, CEO of Gotham Therapeutics. It is believed that development of the technology could have a significant impact on the treatment of numerous health problems, including cancers, autoimmune disorders and neurodegenerative diseases.
Gotham Therapeutics has secured $54m in series A financing to develop its RNA-modifying protein therapies. The investment was led by Versant Ventures, Forbion and S.R. One, with support from Celgene and Alexandria Venture Investments. “Versac’s investments are a testament to the strength of our team at Gotham Therapeutics,” said Dr. David A. Cohen, CEO of Gotham Therapeutics. It is believed that development of the technology could have a significant impact on the treatment of numerous health problems, including cancers, autoimmune disorders and neurodegenerative diseases.